<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2018.81008</article-id><article-id pub-id-type="publisher-id">WJCR-23508</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20180100000_42667304.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  雌二醇E2通过调控PEDF表达促进乳腺癌增殖作用研究
  The Effect of Estradiol E2 on the Proliferation of Breast Cancer by Regulating PEDF Expression
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>洪</surname><given-names>宏海</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>卫琴</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>希才</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>遥</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>广州医科大学附属第三医院检验科，广东 广州</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>gaolaosao@126.com(洪宏)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2017</year></pub-date><volume>08</volume><issue>01</issue><fpage>49</fpage><lpage>54</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨雌二醇E2通过调控色素上皮细胞衍生因子PEDF促进乳腺癌增殖的分子机制。方法：ELISA法检测血清中PEDF水平；放射免疫分析法检测雌二醇E2水平；Western blot检测雌二醇对PEDF调控作用；分子克隆过表达PEDF研究其在雌二醇E2促进乳腺癌增殖中作用；MTT法检测乳腺癌细胞株MCF-7的增殖能力。结果：乳腺癌中PEDF表达下调，且与雌二醇E2水平呈负相关(R = −0.69; ***P &lt; 0.001)；雌二醇E2可下调PEDF的表达，促进乳腺癌细胞MCF-7的增殖。结论：雌二醇E2通过调控PEDF表达进而促进乳腺癌的增殖。 Objective: To investigate the molecular mechanism of estradiol E2 to promote the proliferation of breast cancer by regulating the expression PEDF. Methods: Serum PEDF level was detected by ELISA kit and estradiol E2 level was detected by radioimmunoassay; the effect of estradiol on the PEDF regulation was detected by Western blot; the proliferation of breast cancer cell line MCF-7 was detected by MTT assay. Results: The expression of PEDF was down regulated in breast cancer, and negatively correlated with estradiol E2 level. Estradiol E2 can reduce the expression of PEDF and promote the proliferation of breast cancer cell MCF-7. Conclusion: Estradiol E2 can promote the proliferation of breast cancer by regulating the expression of PEDF.
    
  
 
</p></abstract><kwd-group><kwd>乳腺癌，雌二醇E2，色素上皮细胞衍生因子PEDF，增殖, Breast Cancer</kwd><kwd> Estradiol E2</kwd><kwd> Pigment Epithelial Cell Derived Factor PEDF</kwd><kwd> Proliferation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>雌二醇E2通过调控PEDF表达促进乳腺癌增殖作用研究<sup> </sup></title><p>洪宏海<sup>*</sup>，杨卫琴，唐希才，冯遥<sup>#</sup></p><p>广州医科大学附属第三医院检验科，广东 广州</p><disp-formula id="hanspub.23508-formula57"><graphic xlink:href="//html.hanspub.org/file/8-2150133x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年1月3日；录用日期：2018年1月17日；发布日期：2018年1月24日</p><disp-formula id="hanspub.23508-formula58"><graphic xlink:href="//html.hanspub.org/file/8-2150133x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨雌二醇E2通过调控色素上皮细胞衍生因子PEDF促进乳腺癌增殖的分子机制。方法：ELISA法检测血清中PEDF水平；放射免疫分析法检测雌二醇E2水平；Western blot检测雌二醇对PEDF调控作用；分子克隆过表达PEDF研究其在雌二醇E2促进乳腺癌增殖中作用；MTT法检测乳腺癌细胞株MCF-7的增殖能力。结果：乳腺癌中PEDF表达下调，且与雌二醇E2水平呈负相关(R = −0.69; ***P &lt; 0.001)；雌二醇E2可下调PEDF的表达，促进乳腺癌细胞MCF-7的增殖。结论：雌二醇E2通过调控PEDF表达进而促进乳腺癌的增殖。</p><p>关键词 :乳腺癌，雌二醇E2，色素上皮细胞衍生因子PEDF，增殖</p><disp-formula id="hanspub.23508-formula59"><graphic xlink:href="//html.hanspub.org/file/8-2150133x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-2150133x8_hanspub.png" /> <img src="//html.hanspub.org/file/8-2150133x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>乳腺癌是最常见的恶性肿瘤，其在女性恶性肿瘤中排第一 [<xref ref-type="bibr" rid="hanspub.23508-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.23508-ref2">2</xref>] 。乳腺癌的发病机制复杂多样，其具体分子机制尚未清楚 [<xref ref-type="bibr" rid="hanspub.23508-ref3">3</xref>] 。大多数患者在诊断时已经处于晚期，其生存期一般小于1年 [<xref ref-type="bibr" rid="hanspub.23508-ref4">4</xref>] ，且发生远处转移 [<xref ref-type="bibr" rid="hanspub.23508-ref4">4</xref>] 。研究发现乳腺癌病人血清中雌二醇异常增高，且与乳腺癌发生发展密切相关 [<xref ref-type="bibr" rid="hanspub.23508-ref5">5</xref>] ，随后研究发现雌二醇可促进乳腺癌的增殖，但是其详细分子尚未清楚。色素上皮衍生因子(PEDF, Pigment epithelium-derived factor)属于丝氨酸蛋白酶抑制剂(serpin, serine proteinase inhibitor)超家族，分子量为50 KD。PEDF由视网膜上皮细胞分泌，具有促进视网膜神经分化作用。随后的研究发现，PEDF有着非常多且复杂的生理和病理作用，不仅具有神经分化作用，还具有抗血管新生、诱导肿瘤凋亡、抑制肿瘤转移等作用 [<xref ref-type="bibr" rid="hanspub.23508-ref6">6</xref>] 。文献报道乳腺癌中PEDF表达下调，且抑制乳腺癌的转移和生长 [<xref ref-type="bibr" rid="hanspub.23508-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.23508-ref8">8</xref>] 。但是，PEDF在雌二醇促进乳腺癌增殖中作用尚未清楚。</p><p>在这篇论文中，我们首先检测肝癌病人血清和乳腺癌细胞中PEDF的表达，同时分析其与雌二醇E2的相关性；研究雌二醇E2调控PEDF的作用以及探讨PEDF在雌二醇E2促进乳腺癌细胞增殖中作用。</p></sec><sec id="s4"><title>2. 材料与方法</title><p>标本收集</p><p>健康人和乳腺癌病人血清来自广州医科大学附属第三医院体检中心和检验科。所有病人资料和标本收集都严格按照广州医科大学和暨南大学伦理委员会相关规定。</p><p>试剂和耗材</p><p>雌二醇E2检测试剂盒购自罗氏公司。PEDFELISA检测试剂盒购自Abcam公司。PEDF和β-actin一抗购自CST公司。MTT购自北京鼎国公司。细胞培养皿购自康宁公司。Western blot相关试剂购自北京鼎国。Lipo2000转染试剂购自Invitrogen公司。雌二醇购自Sigma公司。</p><p>PEDF过表达质粒构建及转染</p><p>PEDF过表达质粒构建以及转染步骤参见我们以前发表的文献 [<xref ref-type="bibr" rid="hanspub.23508-ref8">8</xref>] 。具体步骤如下：提取乳腺癌细胞RNA，转录为cDNA，设计PEDF引物，钓取PDEF片段，通过酶切连接到pcDNA3.1+载体上面。转染步骤：MCF-7细胞接种于六孔板中，待其融合度为60%左右，用转染试剂Lipo2000转染PEDF过表达质粒，6个小时后换液，24小时后进行MTT实验。</p><p>MTT法检测乳腺癌细胞增殖能力 [<xref ref-type="bibr" rid="hanspub.23508-ref8">8</xref>]</p><p>MTT法，即噻唑兰颜色反应法，是反映细胞增殖活力的测定方法。活细胞里面线粒体琥珀酸脱氢酶能使MTT还原为不溶于水的蓝紫色晶体——甲缵，并沉淀在细胞里面，而死细胞则并不能使细胞里面的甲缵沉淀。取对数生长期乳腺癌细胞MCF-7，接种到48孔细胞培养板中，每孔加入500 ml细胞悬液，置于37℃、5% CO<sub>2</sub> cell incubator中培养；细胞贴壁后其融合度达到60%左右，瞬时转染PEDF过表达质粒，48 h加入200 &#181;l的MTT工作液(浓度为5 mg/ml)，继续培养4小时；去掉上清后每孔加入2 ml dimethyl sulfoxide (二甲基亚砜，DMSO)，用摇床震荡摇匀，以使蓝色结晶颗粒甲缵完全溶解，用酶标仪测定OD<sub>570</sub>的光密度值。实验中每个实验组设置3个重复的培养孔，重复进行3次。</p><p>ELISA检测乳腺癌病人血清中PEDF含量</p><p>PEDF ELISA试剂盒用来检测乳腺癌病人血清中PEDF的含量，具体步骤参见说明书。详细步骤如下：收集乳腺癌病人血清，12,000转/min离心10 min，吸取上清部分转移到干净无菌的EP管中。往96孔板中加入100 &#181;l乳腺癌血清，37˚孵育90 min，去掉孔里液体，加入生物素标记的抗体，37˚孵育60 min，用PBS洗3遍，随后加入ABC工作液，37˚孵育30 min，用PBS洗3遍，加入90 &#181;l TMB液体，37˚孵育30 min，加入100 &#181;l终止液，450 nM检测OD值。</p><p>Western blot实验</p><p>Western blot实验用来检测PEDF蛋白水平，具体实验方案如下：收集处理好的MCF-7和NMuMG细胞蛋白，进行蛋白定量，跑胶。加入PEDF一抗，4度过夜，收集一抗，加入二抗，然后加入ECL显色，拍照。</p><p>统计学分析</p><p>采用SPSS17.0软件进行统计学处理。计量资料以均数&#177;标准差表示。血清中雌二醇E2水平和PEDF水平采用t检验。雌二醇E2水平和PEDF水平相关性采用Pearson相关性分析。P &lt; 0.05表示具有统计学意义。</p></sec><sec id="s5"><title>3. 实验结果</title><p>乳腺癌中PEDF表达含量下调</p><p>我们选取雌二醇E2受体阳性乳腺癌细胞MCF-7，用永生化的乳腺上皮细胞NMuMG作为对照组，Western blot检测PEDF的表达。结果显示，相对于永生化的乳腺上皮细胞NMuMG，乳腺癌细胞MCF-7的PEDF表达明显下调(图1(a))。因为PEDF可分泌到血液中，因此我们分别收集30例健康人和乳腺癌病人的血清，检测血清中PEDF含量。与健康人相比，乳腺癌病人血清中PEDF也明显下降(图1(b)，P &lt; 0.05)，表明乳腺癌病人PEDF表达下调。</p><p>乳腺癌病人雌二醇E2与PEDF呈负相关</p><p>雌二醇E2与乳腺癌发生、发病、增殖密切相关 [<xref ref-type="bibr" rid="hanspub.23508-ref5">5</xref>] 。因此，我们下一步研究乳腺癌病人雌二醇E2与PEDF相关性(***P &lt; 0.001)。结果显示，乳腺癌病人雌二醇E2与PEDF呈负相关(图2)。</p><p>雌二醇E2下调PEDF蛋白水平</p><p>上面研究显示雌二醇E2水平与PEDF水平密切相关。下一步我们进一步在体外细胞水平研究雌二醇E2对PEDF调控作用。用雌二醇E2蛋白处理MCF-7细胞48小时后，Western blot检测PEDF的表达。结果显示，雌二醇E2明显下调乳腺癌细胞MCF-7的PEDF表达，提示着雌二醇E2可能通过调控PEDF</p><p>图1. 乳腺癌中PEDF的表达</p><p>图2. 乳腺癌病人血清中PEDF水平与雌二醇E2水平相关性分析</p><p>促进乳腺癌增殖(图3)。</p><p>雌二醇E2通过调控PEDF水平促进乳腺癌细胞增殖</p><p>文献报道雌二醇E2促进乳腺癌的增殖 [<xref ref-type="bibr" rid="hanspub.23508-ref5">5</xref>] 。PEDF抑制乳腺癌生长 [<xref ref-type="bibr" rid="hanspub.23508-ref8">8</xref>] 。前面结果提示雌二醇E2下调PEDF的表达，为了进一步证明PEDF在雌二醇E2促进乳腺癌增殖中作用，我们构建PEDF过表达质粒，在雌二醇E2处理乳腺癌细胞MCF-7的同时过表达PEDF，观察其是否影响雌二醇E2对乳腺癌细胞MCF-7增殖作用。结果显示，过表达PEDF后，PEDF的转录水平明显升高(图4(a)，***P &lt; 0.001)。过表达PEDF后，抑制了雌二醇E2促进乳腺癌细胞增殖作用(图4(b))，表明雌二醇E2通过调控PEDF促进乳腺癌细胞的增殖。</p></sec><sec id="s6"><title>4. 讨论</title><p>乳腺癌是女性最常见的恶性肿瘤，其死亡率在恶性肿瘤中排名前列 [<xref ref-type="bibr" rid="hanspub.23508-ref1">1</xref>] 。乳腺癌的发病机制复杂多样，其早期诊断及治疗对病人生存期至关重要 [<xref ref-type="bibr" rid="hanspub.23508-ref9">9</xref>] 。在本论文中，我们发现乳腺癌细胞及乳腺癌病人血清中</p><p>图3. 雌二醇E2下调PEDF蛋白水平</p><p>图4. 雌二醇E2促进乳腺癌细胞增殖作用依赖于PEDF</p><p>PEDF明显下调，且与雌二醇E2呈负相关。进一步研究发现雌二醇E2可下调PEDF水平，且雌二醇E2通过调控PEDF表达进而促进乳腺癌的增殖。</p><p>色素上皮衍生因子(PEDF, Pigment epithelium-derived factor)属于丝氨酸蛋白酶抑制剂(serpin, serine proteinase inhibitor)超家族，其分子量为50KD，在大脑、脊柱、眼睛、肝、肺和血浆等组织中表达 [<xref ref-type="bibr" rid="hanspub.23508-ref10">10</xref>] 。PEDF由视网膜细胞分泌，具有促进视网膜神经分化作用 [<xref ref-type="bibr" rid="hanspub.23508-ref11">11</xref>] 。随后的研究发现，PEDF有着非常多且复杂的生理和病理作用，其不仅具有神经分化作用，还具有抗血管新生、促神经干细胞自我更新、诱导肿瘤凋亡、抗炎、调控脂质代谢、抑制肿瘤转移等功能 [<xref ref-type="bibr" rid="hanspub.23508-ref12">12</xref>] 。我们前期研究表明PEDF抑制乳腺癌的转移和生长 [<xref ref-type="bibr" rid="hanspub.23508-ref8">8</xref>] 。但是，PEDF在乳腺癌病人血清中表达及其调控是如何的尚未清楚。我们实验结果表明，PEDF在乳腺癌细胞和乳腺癌病人血清中表达都下调，与文献报道类似 [<xref ref-type="bibr" rid="hanspub.23508-ref13">13</xref>] 。那么，乳腺癌中PEDF为什么下调呢？</p><p>雌二醇E2是雌性激素的主要活性物质。许多研究表明其与乳腺癌的发生、发展、增殖、转移等密切联系 [<xref ref-type="bibr" rid="hanspub.23508-ref5">5</xref>] 。但是，其与PEDF的关系尚未有文献报道。我们研究表明乳腺癌病人血清雌二醇E2水平与PEDF水平呈负相关，且体外细胞实验证明其可下调PEDF表达，提示着雌二醇E2促进乳腺癌增殖作用与PEDF密切相关。为了进一步验证PEDF参与雌二醇E2促进乳腺癌增殖过程，我们用雌二醇E2处理MCF-7细胞同时过表达PEDF，结果显示雌二醇E2明显促进乳腺癌的增殖，但是，过表达PEDF后明显抑制雌二醇E2促进乳腺癌增殖作用，充分表明雌二醇E2通过调控PEDF促进乳腺癌的增殖作用。</p><p>在这篇论文中，我们分析了乳腺癌病人血清中PEDF与雌二醇E2相关性，体外证明雌二醇E2通过调控PEDF促进乳腺癌细胞增殖作用，阐明雌二醇E2促进乳腺癌增殖分子机制，为将来靶向PEDF治疗乳腺癌提供实验依据和理论基础。</p></sec><sec id="s7"><title>文章引用</title><p>洪宏海,杨卫琴,唐希才,冯 遥. 雌二醇E2通过调控PEDF表达促进乳腺癌增殖作用研究The Effect of Estradiol E2 on the Proliferation of Breast Cancer by Regulating PEDF Expression[J]. 世界肿瘤研究, 2018, 08(01): 49-54. http://dx.doi.org/10.12677/WJCR.2018.81008</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.23508-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Patel, H.K. and Bihani, T. (2017) Selective Estrogen Receptor Modulators (SERMS) and Selective Estrogen Receptor Degraders (SERDs) in Cancer Treatment. Pharmacology &amp; Therapeutics, in Press.  
&lt;br&gt;https://doi.org/10.1016/j.pharmthera.2017.12.012</mixed-citation></ref><ref id="hanspub.23508-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Patel, S. (2017) Breast Cancer: Lesser-Known Facets and Hypotheses. Biomedicine &amp; Pharmacotherapy, 98, 499-506.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2017.12.087</mixed-citation></ref><ref id="hanspub.23508-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Weigelt, B., Peterse, J.L. and van’t Veer, L.J. (2005) Breast Cancer Metastasis: Markers and Models. Nature Reviews Cancer, 5, 591-602. &lt;br&gt;https://doi.org/10.1038/nrc1670</mixed-citation></ref><ref id="hanspub.23508-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kodack, D.P., et al. (2015) Emerging Strategies for Treating Brain Metastases from Breast Cancer. Cancer Cell, 27, 163-175. &lt;br&gt;https://doi.org/10.1016/j.ccell.2015.01.001</mixed-citation></ref><ref id="hanspub.23508-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Majumder, A., Singh, M. and Tyagi, S.C. (2017) Post-Menopausal Breast Cancer: From Estrogen to Androgen Receptor. Oncotarget, 8, 102739-102758. &lt;br&gt;https://doi.org/10.18632/oncotarget.22156</mixed-citation></ref><ref id="hanspub.23508-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bilak, M.M., et al. (1999) Pigment Ep-ithelium-Derived Factor (PEDF) Protects Motor Neurons from Chronic Glutamate-Mediated Neurodegeneration. Journal of Neuropathology &amp; Experimental Neurology, 58, 719-728.  
&lt;br&gt;https://doi.org/10.1097/00005072-199907000-00006</mixed-citation></ref><ref id="hanspub.23508-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Becerra, S.P. (2006) Focus on Molecules: Pigment Ep-ithelium-Derived Factor (PEDF). Experimental Eye Research, 82, 739-740. &lt;br&gt;https://doi.org/10.1016/j.exer.2005.10.016</mixed-citation></ref><ref id="hanspub.23508-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hong, H., Zhou, T., Fang, S., et al. (2014) Pigment Epithe-lium-Derived Factor (PEDF) Inhibits Breast Cancer Metastasis by Down-Regulating Fibronectin. Breast Cancer Re-search and Treatment, 148, 61-72.  
&lt;br&gt;https://doi.org/10.1007/s10549-014-3154-9</mixed-citation></ref><ref id="hanspub.23508-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bae, Y.K., et al. (2013) Fibronectin Expression in Carcinoma Cells Correlates with Tumor Aggressiveness and Poor Clinical Outcome in Patients with Invasive Breast Cancer. Human Pathology, 44, 2028-2037.  
&lt;br&gt;https://doi.org/10.1016/j.humpath.2013.03.006</mixed-citation></ref><ref id="hanspub.23508-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sawant, S., et al. (2004) Regulation of Factors Controlling Angiogenesis in Liver Development: A Role for PEDF in the Formation and Maintenance of Normal Vasculature. Bi-ochemical and Biophysical Research Communications, 325, 408-413. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2004.10.041</mixed-citation></ref><ref id="hanspub.23508-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Filleur, S., et al. (2009) Characterization of PEDF: A Mul-ti-Functional Serpin Family Protein. Journal of Cellular Biochemistry, 106, 769-775. &lt;br&gt;https://doi.org/10.1002/jcb.22072</mixed-citation></ref><ref id="hanspub.23508-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bouck, N. (2002) PEDF: Anti-Angiogenic Guardian of Ocular Function. Trends in Molecular Medicine, 8, 330-334.  
&lt;br&gt;https://doi.org/10.1016/S1471-4914(02)02362-6</mixed-citation></ref><ref id="hanspub.23508-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cai, J., et al. (2006) Decreased Pigment Epithelium-Derived Factor Expression in Human Breast Cancer Progression. Clinical Cancer Research, 12, 3510-3517. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-06-0094</mixed-citation></ref></ref-list></back></article>